A Study to Evaluate Response Markers to Treat Rheumatoid Arthritis


About this study

Study objective: Define pharmacogenomics markers and clinical phenotype features associated with response to RA treatments. Using electronical medical records data and a blood draw with DNA for genotyping from prospectively recruited patients seen in rheumatology clinic (n=100), we will identify genomic markers and leading phenotype features of responders to routinely used anti-rheumatic medications at 3 and 6 months of treatment based on disease activity score with 28-joint count (DAS28), accounting for socioeconomic factors, comorbidities, RA characteristics and prior anti-rheumatic medication use. We hypothesize that: Patients responding to antirheumatic medication(s) and their combinations share similar phenotype and/or genomic markers.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • All patients with RA diagnosed after 1995:
    • Diagnosis defined as a clinical diagnosis by a rheumatologist.
  • Active disease (CDAI > 2.8).
  • Participants who are following up with Mayo Clinic rheumatology providers in Rochester, MN.

Exclusion Criteria:

  • None for main study cohort.
  • Subaim:
    • No prior anti-inflammatory treatment (conventional DMARDs, targeted synthetic DMARDs and biologic DMARDs);
    • No exposure to metformin
    • Prednisone dose > 15mg per day within 7 days of blood draw.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Elena Myasoedova, M.D., Ph.D.

Open for enrollment

Contact information:

Kathleen McCarthy-Fruin M.S.

(507) 284-4797


More information


Publications are currently not available